Automatic Oxygen Control Compared With Manual Adjustment in Hospitalized COPD Patients
Tests an automatic oxygen-control device against manual adjustment in hospitalized adults with COPD.
Plain-language title generated from the registry record
Registry title: Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
Key facts
- Where
- Birmingham, Des Moines, New York, and Philadelphia, United StatesSee the 4 sites
Where in United States
- The University of Alabama at BirminghamBirmingham, United StatesTaking people
- Central Iowa Hospital Corp - UnityPoint HealthDes Moines, United StatesTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesTaking people
- Temple University HospitalPhiladelphia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fisher and Paykel Healthcare
- Trial code
- NCT07222410
- Record updated
- 23 June 2026
- Original description
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.Read full original descriptionShow less
Closed Loop Oxygen Control in COPD Patients Treated With Nasal High Flow in the Hospital
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
Inclusion: Has cognitive ability to provide informed consent; Aged 22 years or older; Hospitalized with hypoxemia/respiratory distress; Diagnosis of COPD; Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator; Expected duration of oxygen and nasal high flow therapy >24 hours (not necessarily continuous).
Exclusion: Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines; Patient receiving end of life care; Nasal or facial conditions precluding use of nasal high flow; Cognitive impairment or impaired consciousness precluding informed consent; Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included; The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator; Hemodynamic instability (systolic blood pressure <90mmHg or requirement for vasopressor or inotropic support); Pregnancy or breastfeeding; Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator; Has already participated in this clinical trial.